Evidence map›Paper›PMID 42482086›Full record

ArticleBMC medical genomics2026

DR.DEGMON: self-explainable deep neural network for drug-induced cell viability prediction incorporating differentially expressed genes and gene ontology.

Wootaek Lim, Jitae Kim, Songhyeon Kim, Hyunsu Bong, Kwang-Su Park, Minji Jeon

Abstract read
In one paragraph

Article in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wootaek LimDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Korea.
Jitae KimDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Korea.
Songhyeon KimDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Korea.
Hyunsu BongDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Korea.
Kwang-Su ParkCollege of Pharmacy, Keimyung University, Daegu, 42601, Korea. parkks@kmu.ac.kr.
Minji JeonDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, 02841, Korea. mjjeon@korea.ac.kr.ORCID http://orcid.org/0000-0001-5731-6186

Funding

MSIT IITP-2026-RS-2022-00156439MSIT IITP-2026-RS-2024-00438263National Research Foundation of Korea NRF2022R1F1A1070111
6 · The paper itself

Abstract

backgroundAccurate prediction of cancer drug responses is essential for advancing cancer treatment strategies and drug development. With the increasing availability of large-scale pharmacogenomic datasets, many deep learning models have been proposed to predict cancer drug responses. However, many existing models lack the capacity to offer critical biomedical insights, such as providing interpretability regarding the potential mechanism of action.

methodsWe propose DR.DEGMON (Drug Response prediction using Differentially Expressed Genes with Multi-layer perceptron integrating gene Ontology Network), a self-explainable deep neural network designed to predict the viability of pan-cancer cell lines in response to drug treatments by utilizing differentially expressed genes. DR.DEGMON leverages prior biological knowledge by incorporating Gene Ontology (GO) into the hierarchical structure of a multi-layer perceptron. The architecture of DR.DEGMON highlights key genes and GO terms that contribute to drug responses through layer-wise relevance propagation (LRP), suggesting potential biological pathways associated with specific drugs.

resultsDR.DEGMON achieved a Pearson correlation coefficient of 0.8568 for cell viability prediction, outperforming all baseline models. The model also showed robust generalization performance on external datasets, including GDSC, PRISM, and CCLE. In addition, we employed layer-wise relevance propagation (LRP) to obtain relevance scores for input genes and nodes representing GO terms.

conclusionDR.DEGMON shows high performance in predicting drug responses and provides interpretable results. The integration of GO and LRP enabled the model to suggest the underlying biological processes involved in drug responses, making it a valuable tool for predicting outcomes and discovering new biomedical knowledge in cancer pharmacogenomics. This approach offers both practical utility in drug development and a method for improving the understanding of cancer biology.

Indexed as

Antineoplastic AgentsComputational BiologyDeep LearningGene Expression Regulation, NeoplasticGene OntologyNeural Networks, ComputerCell Line, TumorCell SurvivalGene Expression ProfilingHumansAntineoplastic AgentsCancer drug response predictionDifferentially expressed genesGene OntologySelf-explainable artificial intelligence

Identifiers

PMID42482086
PMCPMC13410581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.